Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Regional Development
  • Published:

Is consolidation the only option for UK biotech?

Nature Biotechnology volume 17, pages 31–32 (1999)Cite this article

Abstract

Yes, if it is to have the resources needed to develop products of interest to large pharmaceutical partners.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Richard Trevillion is a director and Allison Fleetwood is an executive at Arthur Andersen Corporate Finance– Healthcare, 1 Surrey Street, London, WC2R 2NT, UK

    Richard Trevillion & Allison Fleetwood

Authors
  1. Richard Trevillion
    View author publications

    Search author on:PubMed Google Scholar

  2. Allison Fleetwood
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trevillion, R., Fleetwood, A. Is consolidation the only option for UK biotech?. Nat Biotechnol 17 (Suppl 3), 31–32 (1999). https://doi.org/10.1038/9104

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/9104

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing